{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:28:49Z","timestamp":1785414529844,"version":"3.56.0"},"posted":{"date-parts":[[2025,11,6]]},"group-title":"Neuroscience","reference-count":62,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["4RF1AG055549-03"],"award-info":[{"award-number":["4RF1AG055549-03"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U19AG063744"],"award-info":[{"award-number":["U19AG063744"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U01AG061359"],"award-info":[{"award-number":["U01AG061359"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AG081322"],"award-info":[{"award-number":["R01AG081322"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AG069901"],"award-info":[{"award-number":["R01AG069901"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U19AG074879"],"award-info":[{"award-number":["U19AG074879"]}],"id":[{"id":"https:\/\/ror.org\/001d55x84","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Asymptomatic Alzheimer\u2019s disease (AsymAD) refers to individuals who, despite exhibiting amyloid-\u03b2 plaques and tau pathology comparable to Alzheimer\u2019s disease (AD), maintain cognitive performance similar to cognitively normal individuals. The resilience mechanism in these AsymAD individual remains understudied. We performed a systematic analysis comparing AsymAD and AD across multiple cohorts (ROSMAP, Banner and Mount Sinai), brain regions (BA6, BA9, BA36 and BA37) and neuronal and glial cell types using proteomics and transcriptomics data. AsymAD brains exhibited preserved mitochondrial bioenergetics, characterized by enhanced oxidative phosphorylation (OXPHOS), electron transport chain (ETC) activity, fatty acid and lipid metabolism, and branched-chain amino acid (BCAA) utilization. Pathways regulating mitochondrial complex biogenesis and calcium homeostasis were also upregulated. Key mitochondrial proteins such as MRPL47, CPT2, BCAT2, and IDH2, were consistently upregulated in AsymAD, whereas MACROD1 was downregulated. At the cellular level, excitatory neurons, including superficial, mid-layer, and deep-layer subtypes, exhibited the most preserved mitochondrial function, whereas vulnerable inhibitory subtypes, including PVALB and SST neurons, showed increased cellular abundance and bioenergetic activity. In contrast, microglia and oligodendrocytes proportions were reduced in AsymAD relative to AD. Our findings identify preserved mitochondrial bioenergetics as a defining feature of resilience in AD and suggest that enhancing NADH metabolism via NAD+ precursor-based interventions may potentially help in maintaining cognitive function despite amyloid and tau pathology.<\/jats:p>","DOI":"10.1101\/2025.11.04.686626","type":"posted-content","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:15:24Z","timestamp":1762460124000},"source":"Crossref","is-referenced-by-count":1,"title":["Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer\u2019s disease"],"prefix":"10.64898","author":[{"given":"Purba","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Trushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-4941","authenticated-orcid":false,"given":"Priyanka","family":"Baloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025110923501140000_2025.11.04.686626v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.7437"},{"key":"2025110923501140000_2025.11.04.686626v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0289-8"},{"key":"2025110923501140000_2025.11.04.686626v1.3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"2025110923501140000_2025.11.04.686626v1.4","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","year":"2016","journal-title":"The Lancet"},{"key":"2025110923501140000_2025.11.04.686626v1.5","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv-2024-z4k0k"},{"key":"2025110923501140000_2025.11.04.686626v1.6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b240 vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2025110923501140000_2025.11.04.686626v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt82"},{"key":"2025110923501140000_2025.11.04.686626v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"2025110923501140000_2025.11.04.686626v1.9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/alz.12235","article-title":"Open Peer Commentary to \u201cFailure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019\u201d","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025110923501140000_2025.11.04.686626v1.10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051022-043645"},{"key":"2025110923501140000_2025.11.04.686626v1.11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/alz.12235","article-title":"Open Peer Commentary to \u201cFailure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019\u201d","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025110923501140000_2025.11.04.686626v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2025110923501140000_2025.11.04.686626v1.13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt171"},{"key":"2025110923501140000_2025.11.04.686626v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv048"},{"key":"2025110923501140000_2025.11.04.686626v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-021-00999-y"},{"key":"2025110923501140000_2025.11.04.686626v1.16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40478-024-01760-9","article-title":"Gene-expression profiling of individuals resilient to Alzheimer\u2019s disease reveals higher expression of genes related to metallothionein and mitochondrial processes and no changes in the unfolded protein response","volume":"12","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"2025110923501140000_2025.11.04.686626v1.17","doi-asserted-by":"crossref","unstructured":"Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci Adv 6, (2020).","DOI":"10.1126\/sciadv.aaz9360"},{"key":"2025110923501140000_2025.11.04.686626v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2023.102747"},{"key":"2025110923501140000_2025.11.04.686626v1.19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-024-00409-w","article-title":"Focusing on mitochondria in the brain: from biology to therapeutics","volume":"13","year":"2024","journal-title":"Transl Neurodegener"},{"key":"2025110923501140000_2025.11.04.686626v1.20","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.21.590464"},{"key":"2025110923501140000_2025.11.04.686626v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.09.055"},{"key":"2025110923501140000_2025.11.04.686626v1.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.163824"},{"key":"2025110923501140000_2025.11.04.686626v1.23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1326-9-16","article-title":"Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP\/Ld transgenic mouse model of Alzheimer\u2019s disease","volume":"9","year":"2014","journal-title":"Mol Neurodegener"},{"key":"2025110923501140000_2025.11.04.686626v1.24","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12655"},{"key":"2025110923501140000_2025.11.04.686626v1.25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13024-024-00719-7","article-title":"The concept of resilience to Alzheimer\u2019s Disease: current definitions and cellular and molecular mechanisms","volume":"19","year":"2024","journal-title":"Mol Neurodegener"},{"key":"2025110923501140000_2025.11.04.686626v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2022.02.005"},{"key":"2025110923501140000_2025.11.04.686626v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-025-02032-y"},{"key":"2025110923501140000_2025.11.04.686626v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0132-6"},{"key":"2025110923501140000_2025.11.04.686626v1.29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s42003-020-1079-x","article-title":"\u03b2-amyloid and tau drive early Alzheimer\u2019s disease decline while glucose hypometabolism drives late decline","volume":"3","year":"2020","journal-title":"Commun Biol"},{"key":"2025110923501140000_2025.11.04.686626v1.30","doi-asserted-by":"crossref","first-page":"16838","DOI":"10.1038\/s41598-025-01927-x","article-title":"Coupling relationship between glucose and oxygen metabolisms to serve as an imaging biomarker for Alzheimer\u2019s disease","volume":"15","year":"2025","journal-title":"Sci Rep"},{"key":"2025110923501140000_2025.11.04.686626v1.31","doi-asserted-by":"crossref","first-page":"e70180","DOI":"10.1002\/hbm.70180","article-title":"Relationships Between Brain Glucose Metabolism Patterns and Impaired Glycemic Status: A Systematic Review of FDG-PET Studies With a Focus on Alzheimer\u2019s Disease","volume":"46","year":"2025","journal-title":"Hum Brain Mapp"},{"key":"2025110923501140000_2025.11.04.686626v1.32","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41467-025-57032-0","article-title":"Individual bioenergetic capacity as a potential source of resilience to Alzheimer\u2019s disease","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"2025110923501140000_2025.11.04.686626v1.33","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.25.640178"},{"key":"2025110923501140000_2025.11.04.686626v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1011"},{"key":"2025110923501140000_2025.11.04.686626v1.35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010933404324"},{"key":"2025110923501140000_2025.11.04.686626v1.36","doi-asserted-by":"crossref","unstructured":"Friedman, J. H . Greedy function approximation: A gradient boosting machine. The Annals of Statistics 29, (2001).","DOI":"10.1214\/aos\/1013203451"},{"key":"2025110923501140000_2025.11.04.686626v1.37","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012487302797"},{"key":"2025110923501140000_2025.11.04.686626v1.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x"},{"key":"2025110923501140000_2025.11.04.686626v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.08.039"},{"key":"2025110923501140000_2025.11.04.686626v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07606-7"},{"key":"2025110923501140000_2025.11.04.686626v1.41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0844-5"},{"key":"2025110923501140000_2025.11.04.686626v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19622-y"},{"key":"2025110923501140000_2025.11.04.686626v1.43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41467-023-36519-8","article-title":"Single-cell RNA-sequencing identifies disease-associated oligodendrocytes in male APP NL-G-F and 5XFAD mice","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2025110923501140000_2025.11.04.686626v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2021.06.010"},{"key":"2025110923501140000_2025.11.04.686626v1.45","doi-asserted-by":"crossref","unstructured":"Jiang, W. et al. CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation. Sci Adv 9, (2023).","DOI":"10.1126\/sciadv.adg8148"},{"key":"2025110923501140000_2025.11.04.686626v1.46","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.14.21263565"},{"key":"2025110923501140000_2025.11.04.686626v1.47","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41467-025-57032-0","article-title":"Individual bioenergetic capacity as a potential source of resilience to Alzheimer\u2019s disease","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"2025110923501140000_2025.11.04.686626v1.48","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.26.656116"},{"key":"2025110923501140000_2025.11.04.686626v1.49","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10555-024-10216-4","article-title":"Mitochondrial ribosomal proteins in metastasis and their potential use as prognostic and therapeutic targets","volume":"43","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"2025110923501140000_2025.11.04.686626v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.04.037"},{"key":"2025110923501140000_2025.11.04.686626v1.51","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s007020070011","article-title":"No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia","volume":"107","year":"2000","journal-title":"J Neural Transm (Vienna"},{"key":"2025110923501140000_2025.11.04.686626v1.52","first-page":"27","article-title":"Treatment of Alzheimer\u2019s disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study","volume":"30","year":"2004","journal-title":"Drugs Exp Clin Res"},{"key":"2025110923501140000_2025.11.04.686626v1.53","first-page":"1","article-title":"Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type","volume":"26","year":"1996","journal-title":"Ann Clin Lab Sci"},{"key":"2025110923501140000_2025.11.04.686626v1.54","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1089\/ars.2023.0354","article-title":"NAD + Precursors in Human Health and Disease: Current Status and Future Prospects","volume":"39","year":"2023","journal-title":"Antioxid Redox Signal"},{"key":"2025110923501140000_2025.11.04.686626v1.55","doi-asserted-by":"publisher","DOI":"10.14336\/ad.2021.0523"},{"key":"2025110923501140000_2025.11.04.686626v1.56","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. NAD+ in Alzheimer\u2019s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo. Front Cell Dev Biol 9, (2021).","DOI":"10.3389\/fcell.2021.668491"},{"key":"2025110923501140000_2025.11.04.686626v1.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2025.03.013"},{"key":"2025110923501140000_2025.11.04.686626v1.58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.tig.2024.11.010","article-title":"Mitochondrial-derived microproteins: from discovery to function","volume":"41","year":"2025","journal-title":"Trends in Genetics"},{"key":"2025110923501140000_2025.11.04.686626v1.59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41380-023-02344-0","article-title":"A naturally occurring variant of SHLP2 is a protective factor in Parkinson\u2019s disease","volume":"29","year":"2024","journal-title":"Mol Psychiatry"},{"key":"2025110923501140000_2025.11.04.686626v1.60","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1038\/s41467-023-40082-7","article-title":"Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"2025110923501140000_2025.11.04.686626v1.61","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01769-3"},{"key":"2025110923501140000_2025.11.04.686626v1.62","doi-asserted-by":"crossref","first-page":"e14153","DOI":"10.1111\/acel.14153","article-title":"Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4-induced brain pathology","volume":"23","year":"2024","journal-title":"Aging Cell"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.04.686626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:58:23Z","timestamp":1768471103000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.11.04.686626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1101\/2025.11.04.686626","relation":{},"subject":[],"published":{"date-parts":[[2025,11,6]]},"subtype":"preprint"}}